Clinical Scorecard: Pre-transplant detection of measurable residual disease via flow cytometry serves as an independent prognostic indicator in children with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation
At a Glance
Category
Detail
Condition
Pediatric Acute Myeloid Leukemia (AML)
Key Mechanisms
Pre-transplant measurable residual disease (MRD) detection via multiparameter flow cytometry (MFC) and high-risk fusion genes impact survival outcomes.
Target Population
Children with newly diagnosed AML undergoing allo-HSCT
Care Setting
Pediatric hematology center
Key Highlights
Pre-transplant MFC-MRD positivity is an independent adverse prognostic factor for survival.
3-year disease-free survival (DFS) rate is 85.5% ± 4.2%; overall survival (OS) rate is 86.8% ± 4.1%.
High-risk fusion genes are associated with increased relapse risk post-transplant.
Study included 80 pediatric AML patients treated according to the C-HUANAN-AML 15 protocol.
Cox regression models confirmed the prognostic significance of pre-transplant MFC-MRD.
Guideline-Based Recommendations
Diagnosis
Comprehensive diagnostic workup including bone marrow morphology, flow cytometric immunophenotyping, cytogenetic analysis, and molecular profiling.
Management
Risk stratification and treatment decisions based on European LeukemiaNet criteria and serial MFC-MRD assessments.
Monitoring & Follow-up
Regular monitoring of measurable residual disease (MRD) using multiparameter flow cytometry.
Risks
Patients with pre-transplant MFC-MRD positivity and high-risk fusion genes are at increased risk of relapse.
Patient & Prescribing Data
Pediatric patients aged ≤ 18 years with newly diagnosed AML.
Patients treated according to the C-HUANAN-AML 15 protocol prior to transplantation.
Clinical Best Practices
Achieve deep remission to reduce tumor burden before transplantation.
Consider intensified post-transplant management strategies, including maintenance therapy for high-risk patients.
